# CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Source: https://onco.cc/trials/nct06834282/  
OnCo record `nct06834282` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CER-1236 run by CERo Therapeutics Holdings, Inc., now recruiting.

## Summary

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) is a phase 1 interventional study registered as NCT06834282 by CERo Therapeutics Holdings, Inc., with 18 participants planned, started 2025-04-07. Conditions recorded: AML, Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia. Interventions recorded: CER-1236, Cyclophosphamide, Fludarabine and Mesna.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06834282
- Phase: 1
- Setting: Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)
- Sponsor: CERo Therapeutics Holdings, Inc.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT06834282: https://clinicaltrials.gov/study/NCT06834282

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)
- drugs: [CER-1236](https://onco.cc/drugs/cer-1236/)
- companies: [CERo Therapeutics](https://onco.cc/companies/cero-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06834282.json